Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_assertion type Assertion NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_head.
- NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_assertion description "[Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_provenance.
- NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_assertion evidence source_evidence_literature NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_provenance.
- NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_assertion SIO_000772 20660056 NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_provenance.
- NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_assertion wasDerivedFrom befree-20150227 NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_provenance.
- NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_assertion wasGeneratedBy ECO_0000203 NP647038.RAmQCT_B8-4UODhIrQc0jWTQ9WfJy8lvFqZLNesL2o_XE130_provenance.